Abstract: The present invention relates to a metabolic biomarker set for assessing kidney disease comprising at least two amino acids, at least two acylcarnitines and at least two biogenic amines. Moreover, the present invention relates to a method for assessing kidney disease in a mammalian subject which comprises obtaining a biological sample, preferably blood and/or urine, from the subject and measuring in the biological sample the amount of at least two amino acids, of at least two acylcarnitines and of at least two biogenic amines, as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess kidney disease.

Abstract: The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7?-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5?,6?-Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a,6a,EPC); and 4?-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.

Abstract: The present invention relates to a metabolic biomarker set for assessing kidney disease comprising at least two amino acids, at least two acylcarnitines and at least two biogenic amines. Moreover, the present invention relates to a method for assessing kidney disease in a mammalian subject which comprises obtaining a biological sample, preferably blood and/or urine, from the subject and measuring in the biological sample the amount of at least two amino acids, of at least two acylcarnitines and of at least two biogenic amines, as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess kidney disease.

Abstract: An apparatus and method analyzes a metabolic profile in a biological sample. The apparatus includes an input unit for inputting the drugs and/or metabolites to be screened; a controlling unit for determining a parameter set for metabolites preparation and for mass spectrometry analysis depending on the input of the kind of metabolites to be screened; a treatment unit for preparing the metabolites to be screened depending on the determined parameter set; a mass spectrometer for performing mass spectrometry analysis on prepared metabolites depending on the parameter set; a database for storing results of analyzing and parameter sets for metabolite preparation and for mass spectrometry analyses; and an evaluation unit for evaluating the results of mass spectrometry by use of reference results stored in the database to output an analysis of the metabolites profile.

Abstract: A device, in particular a sample preparation device for the quantitative analysis of a drug and/or metabolite profile in a biological sample, which includes an insert for such a device being impregnated with at least one internal standard, to the internal standard itself, and to a kit comprising the device. Further, the invention also relates to an apparatus containing the device, and to a method for the quantitative analysis of a drug and/or metabolite profile in a biological sample employing the device.